Differential expression of type 2 3α/type 5 17β- hydroxysteroid dehydrogenase (AKR1C3) in tumors of the central nervous system

International Journal of Clinical and Experimental Pathology

Volumn 3, Issue 8, 2010, Pages 743-754

  Park, Aubrey L ^a   Lin, Hsueh Kung ^a,b   Yang, Qing ^a   Sing, Chor Wing ^c   Fan, Michael ^d   Mapstone, Timothy B ^a   Gross, Naina L ^a   Gumerlock, Mary K ^a   Martin, Michael D ^a   Rabb, Craig H ^a   Fung, Kar Ming ^a,b  

^a UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d RUTGERS UNIVERSITY   (United States)

Author keywords

Akr; Aldo keto reductase; Androgen receptor; Ar; Er; Estrogen receptor; Hsd; Hydroxysteroid dehydrogenase; Peroxisome proliferator activating receptor; Pg; Ppar; Pr; Progesterone receptor; Prostaglandin

Indexed keywords

15 HYDROXYPROSTAGLANDIN DEHYDROGENASE; 3(OR 17)BETA HYDROXYSTEROID DEHYDROGENASE; AKR1C3 PROTEIN, HUMAN; TUMOR MARKER;

ARTICLE; BRAIN TUMOR; ENZYMOLOGY; GLIOMA; HUMAN; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; MENINGIOMA; METABOLISM; NEURILEMOMA; PATHOLOGY;

3-HYDROXYSTEROID DEHYDROGENASES; BRAIN NEOPLASMS; GLIOMA; HUMANS; HYDROXYPROSTAGLANDIN DEHYDROGENASES; IMMUNOHISTOCHEMISTRY; MEDULLOBLASTOMA; MENINGIOMA; NEURILEMMOMA; TUMOR MARKERS, BIOLOGICAL;

EID: 79953156544     PISSN: None     EISSN: 19362625     Source Type: Journal    
DOI: None     Document Type: Article

References (51)

1. Jez JM, Flynn TG and Penning TM. A new nomenclature for the aldo-keto reductase superfamily. Biochem Pharmacol 1997; 54: 639-647.
2. Jez JM, Bennett MJ, Schlegel BP, Lewis M and Penning TM. Comparative anatomy of the aldoketo reductase superfamily. Biochem J 1997; 326: 625-636.
3. Hara A, Matsuura K, Tamada Y, Sato K, Miyabe Y, Deyashiki Y and Ishida N. Relationship of human liver dihydrodiol dehydrogenases to hepatic bile-acid-binding protein and an oxidoreductase of human colon cells. Biochem J 1996; 313: 373-376.
4. Dufort I, Soucy P, Labrie F and Luu-The V. Molecular cloning of human type 3 3α-hydroxysteroid dehydrogenase that differs from 20α-hydroxysteroid dehydrogenase by seven amino acids. Biochem Biophy Res Communication 1996; 228: 474-479.
5. Deyashiki Y, Ogasawara A, Nakayama T, Nakanishi M, Miyabe Y, Sato K and Hara A. Molecular cloning of two human liver 3α-hydroxysteroid/ dihydrodiol dehydrogenase isoenzymes that are identical with chlordecone reductase and bileacid binder. Biochem J 1994; 299: 545-552.
6. Khanna M, Qin KN, Wang RW and Cheng KC. Substrate specificity, gene structure, and tissuespecific distribution of multiple human 3α-hydroxysteroid dehydrogenases. J Biol Chem 1995; 270: 20162-20168.
7. Lin HK, Jez JM, Schlegel BP, Peehl DM, Pachter JA and Penning TM. Expression and characterization of recombinant type 2 3α-hydroxysteroid dehydrogenase (HSD) from human prostate: demonstration of bifunctional 3a/17b-HSD activity and cellular distribution. Mol Endocrinol 1997; 11: 1971-1984.
8. Hyndman D, Bauman DR, Heredia VV and Penning TM. The aldo-keto reductase superfamily homepage. Chem Biol Interact 2003; 143-144: 621-631.
9. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B and Penning TM. Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 2004; 279: 10784-10795.
10. Penning TM, Burczynski ME, Jez JM, Hung CF, Lin HK, Ma H, Moore M, Palackal N and Ratnam K. Human 3α-hydroxysteroid dehydrogenase isoforms (AKR1C1-AKR1C4) of the aldo-keto reductase superfamily: functional plasticity and tissue distribution reveals roles in the inactivation and formation of male and female sex hormones. Biochem J 2000; 351: 67-77.
11. Matsuura K, Shiraishi H, Hara A, Sato K, Deyashiki Y, Ninomiya M and Sakai S. Identification of a principal mRNA species for human 3α-hydroxysteroid dehydrogenase isoform (AKR1C3) that exhibits high prostaglandin D2 11-ketoreductase activity. J Biochem (Tokyo) 1998; 124: 940-946.
12. Penning TM, Steckelbroeck S, Bauman DR, Miller MW, Jin Y, Peehl DM, Fung KM and Lin HK. Aldo-keto reductase (AKR) 1C3: Role in prostate disease and the development of specific inhibitors. Mol Cell Endocrinol 2006; 248: 182-191.
13. Lin HK, Steckelbroeck S, Fung KM, Jones AN and Penning TM. Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/ type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 2004; 69: 795-801.
14. Rizner TL, Smuc T, Rupreht R, Sinkovec J and Penning TM. AKR1C1 and AKR1C3 may determine progesterone and estrogen ratios in endometrial cancer. Mol Cell Endocrinol 2006; 248: 126-135.
15. Ashley RA, Yu Z, Fung KM, Frimberger D, Kropp BP, Penning TM and Lin HK. Developmental evaluation of aldo-keto reductase 1C3 expression in the cryptorchid testis. Urology 2009;
16. Lewis MJ, Wiebe JP and Heathcote JG. Expression of progesterone metabolizing enzyme genes (AKR1C1, AKR1C2, AKR1C3, SRD5A1, SRD5A2) is altered in human breast carcinoma. BMC Cancer 2004; 4: 27.
17. Ito K, Utsunomiya H, Suzuki T, Saitou S, Akahira J, Okamura K, Yaegashi N and Sasano H. 17β-hydroxysteroid dehydrogenases in human endometrium and its disorders. Mol Cell Endocrinol 2006; 248: 136-140.
18. Nakamura Y, Suzuki T, Nakabayashi M, Endoh M, Sakamoto K, Mikami Y, Moriya T, Ito A, Takahashi S, Yamada S, Arai Y and Sasano H. In situ androgen producing enzymes in human prostate cancer. Endocr Relat Cancer 2005; 12: 101-107.
19. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JT, Culkin DJ, Kropp BP, Penning TM and Lin HK. Increased expression of type 2 3α-hydroxysteroid dehydrogenase/ type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 2006; 13: 169-180.
20. Stanbrough M, Bubley G, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG and Balk SP. Increased expression of genes converting adrenal androgens to testosterone in androgenindependent prostate cancer. Cancer Res 2006; 66: 2815-2825.
21. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T and Naito M. Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 2008; 61: 448-454.
22. Azzarello J, Fung KM and Lin HK. Tissue distribution of human AKR1C3 and rat homolog in adult genitourinary system. J Histochem Cytochem 2008; 56: 853-861.
23. Lan Q, Mumford JL, Shen M, Demarini DM, Bonner MR, He X, Yeager M, Welch R, Chanock S, Tian L, Chapman RS, Zheng T, Keohavong P, Caporaso N and Rothman N. Oxidative damagerelated genes AKR1C3 and OGG1 modulate risks for lung cancer due to exposure to PAH-rich coal combustion emissions. Carcinogenesis 2004; 25: 2177-2181.
24. Azzarello JT, Lin H-K, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM and Fung K-M. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Expt Pathol 2009; 3: 147-155.
25. Schule C, Baghai TC, di Michele F, Eser D, Pasini A, Romeo E and Rupprecht R. Mirtazapine does not influence tetrahydrodeoxycorticosterone levels in depressed patients. World J Biol Psychiatry 2010; 11: 308-313.
26. Higashi T, Nagura Y, Shimada K and Toyo'oka T. Studies on neurosteroids XXVI. Fluoxetineevoked changes in rat brain and serum levels of neuroactive androgen, 5α-androstane-3α,17β-diol. Biol Pharm Bull 2009; 32: 1636-1638.
27. Edinger KL and Frye CA. Testosterone's antianxiety and analgesic effects may be due in part to actions of its 5α-reduced metabolites in the hippocampus. Psychoneuroendocrinology 2005; 30: 418-430.
28. Luchetti S, Bossers K, Frajese GV and Swaab DF. Neurosteroid biosynthetic pathway changes in substantia nigra and caudate nucleus in Parkinson's disease. Brain Pathol 2010; 20: 945-951.
29. Azzarello JT, Lin H-K, Gherezghiher A, Zakharov V, Yu Z, Kropp BP, Culkin DJ, Penning TM and Fung K-M. Expression of AKR1C3 in renal cell carcinoma, papillary urothelial carcinoma, and Wilms' tumor. Int J Clin Expt Pathol 2009; 3: 147-155.
30. Zakharov V, Lin HK, Azzarello J, McMeekin S, Moore KN, Penning TM and Fung KM. Suppressed expression of type 2 3α/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) in endometrial hyperplasia and carcinoma. Int J Clin Exp Pathol 2010; 3: 608-617.
31. Weidenfeld J and Schiller H. Metabolism of steroids by human brain tumors. Clin Neuropharmacol 1984; 7: 395-397.
32. Chan PH and Fishman RA. Alterations of membrane integrity and cellular constituents by arachidonic acid in neuroblastoma and glioma cells. Brain Res 1982; 248: 151-157.
33. Urbanska K, Pannizzo P, Lassak A, Gualco E, Surmacz E, Croul S, Del Valle L, Khalili K and Reiss K. Estrogen receptor β-mediated nuclear interaction between IRS-1 and Rad51 inhibits homologous recombination directed DNA repair in medulloblastoma. J Cell Physiol 2009; 219: 392-401.
34. Belcher SM, Ma X and Le HH. Blockade of estrogen receptor signaling inhibits growth and migration of medulloblastoma. Endocrinology 2009; 150: 1112-1121.
35. Batistatou A, Stefanou D, Goussia A, Arkoumani E, Papavassiliou AG and Agnantis NJ. Estrogen receptor beta (ERβ) is expressed in brain astrocytic tumors and declines with dedifferentiation of the neoplasm. J Cancer Res Clin Oncol 2004; 130: 405-410.
36. Carroll RS, Zhang J and Black PM. Expression of estrogen receptors α and β in human meningiomas. J Neurooncol 1999; 42: 109-116.
37. Blankenstein MA, Blaauw G, Lamberts SW and Mulder E. Presence of progesterone receptors and absence of oestrogen receptors in human intracranial meningioma cytosols. Eur J Cancer Clin Oncol 1983; 19: 365-370.
38. Carroll RS, Glowacka D, Dashner K and Black PM. Progesterone receptor expression in meningiomas. Cancer Res 1993; 53: 1312-1316.
39. Maxwell M, Galanopoulos T, Neville-Golden J and Antoniades HN. Expression of androgen and progesterone receptors in primary human meningiomas. J Neurosurg 1993; 78: 456-462.
40. Inoue T, Akahira J, Suzuki T, Darnel AD, Kaneko C, Takahashi K, Hatori M, Shirane R, Kumabe T, Kurokawa Y, Satomi S and Sasano H. Progesterone production and actions in the human central nervous system and neurogenic tumors. J Clin Endocrinol Metab 2002; 87: 5325-5331.
41. Carroll RS, Brown M, Zhang J, DiRenzo J, Font De Mora J and Black PM. Expression of a subset of steroid receptor cofactors is associated with progesterone receptor expression in meningiomas. Clin Cancer Res 2000; 6: 3570-3575.
42. Jay JR, MacLaughlin DT, Riley KR and Martuza RL. Modulation of meningioma cell growth by sex steroid hormones in vitro. J Neurosurg 1985; 62: 757-762.
43. Carroll RS, Zhang JP and Black PM. Hormone receptors in vestibular schwannomas. Acta Neurochir 1997; 139: 188-192.
44. Jaiswal S, Agrawal V, Jaiswal AK, Pandey R and Mahapatra AK. Expression of estrogen and progesterone receptors in vestibular schwannomas and their clinical significance. J Negat Results Biomed 2009; 8: 9.
45. Cafer S, Bayramoglu I, Uzum N, Yilmaz M, Memis L and Uygur K. Expression and clinical significance of Ki-67, oestrogen and progesterone receptors in acoustic neuroma. J Laryngol Otol 2008; 122: 125-127.
46. Markwalder TM, Waelti E and Markwalder RV. Estrogen and progestin receptors in acoustic and spinal neurilemmomas. Clinicopathologic correlations. Surg Neurol 1986; 26: 142-148.
47. Ragel BT, Couldwell WT, Gillespie DL and Jensen RL. Identification of hypoxia-induced genes in a malignant glioma cell line (U-251) by cDNA microarray analysis. Neurosurg Rev 2007; 30: 181-187.
48. Idbaih A, Marie Y, Lucchesi C, Pierron G, Manie E, Raynal V, Mosseri V, Hoang-Xuan K, Kujas M, Brito I, Mokhtari K, Sanson M, Barillot E, Aurias A, Delattre JY and Delattre O. BAC array CGH distinguishes mutually exclusive alterations that define clinicogenetic subtypes of gliomas. Int J Cancer 2008; 122: 1778-1786.
49. Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG and Buckner JC. A t(1;19) (q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 2006; 66: 9852-9861.
50. Ducray F, Idbaih A, de Reynies A, Bieche I, Thillet J, Mokhtari K, Lair S, Marie Y, Paris S, Vidaud M, Hoang-Xuan K, Delattre O, Delattre JY and Sanson M. Anaplastic oligodendrogliomas with 1p19q codeletion have a proneural gene expression profile. Mol Cancer 2008; 7: 41.
51. Bredel M, Scholtens DM, Harsh GR, Bredel C, Chandler JP, Renfrow JJ, Yadav AK, Vogel H, Scheck AC, Tibshirani R and Sikic BI. A network model of a cooperative genetic landscape in brain tumors. JAMA 2009; 302: 261-275.